GENETIC-ANALYSIS OF THE CYP2D LOCUS IN RELATION TO DEBRISOQUINE HYDROXYLATION CAPACITY IN KOREAN, JAPANESE AND CHINESE SUBJECTS

被引:89
作者
DAHL, ML [1 ]
YUE, QY [1 ]
ROH, HK [1 ]
JOHANSSON, I [1 ]
SAWE, J [1 ]
SJOQVIST, F [1 ]
BERTILSSON, L [1 ]
机构
[1] KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN
来源
PHARMACOGENETICS | 1995年 / 5卷 / 03期
关键词
DEBRISOQUINE; MEPHENYTOIN; DRUG METABOLISM; INTERETHNIC DIFFERENCES;
D O I
10.1097/00008571-199506000-00004
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The CYP2D6 genotype and the debrisoquine and mephenytoin hydroxylation phenotypes were studied in 63 Oriental subjects including 21 Chinese, 21 Japanese and 21 Koreans, All subjects were extensive metabolizers of debrisoquine, The incidence of the S-mephenytoin poor metabolizer phenotype was 14% in the Chinese, 24% in the Japanese and 24% in the Korean population, respectively, which is similar to previous reports, The CYP2D6 genotype was analysed by Xba I and Eco RI RFLP, and by allele-specific PCR analysis for the presence of several allelic variants of the CYP2D locus, No CYP2D6A or CYP2D6B alleles, two of the most common defect alleles among Caucasians, were found among the Oriental subjects, The frequency of the CYP2D6D allele was similar to that in Caucasian populations and consistent with the low incidence of the poor metabolizer phenotype in all three Oriental populations, The CYP2D6L(2)-allele with duplication of an active CYP2D6L gene was identified in one Korean and one Chinese allele in association with high CYP2D6 activity, The CYP2D6Ch alleles CYP2D6Ch(1) and Ch(2), identified by RFLP and PCR for the -1338C --> T and 188C --> T mutations, were the most frequent allelic variants in all three populations studied, and were related to a decreased CYP2D6 activity as previously shown in Chinese, In conclusion, the present pilot study revealed major similarities in the polymorphic CYP2D locus between Korean, Japanese and Chinese populations.
引用
收藏
页码:159 / 164
页数:6
相关论文
共 33 条
[1]  
Alvan G., Bechtel P., Iselius L., Gundert-Remy U., Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations, Eur J Clin Pharmacol, 39, pp. 533-537, (1990)
[2]  
Armstrong M., Fairbrother K., Idle J.R., Daly A.K., The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population, Pharmacogenetics, 4, pp. 73-81, (1994)
[3]  
Bertilsson L., Lou Y.-Q., Du Y.-L., Liu Y., Kuang T.-Y., Liao X.-M., Wang K.-Y., Reviriego J., Iselius L., Sjoqvist F., Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and Smephenytoin, Clin Pharmacol Ther, 51, pp. 388-397, (1992)
[4]  
Bertilsson L., Dahl M.-L., Sjoqvist F., Aberg-Wistedt A., Humble M., Johansson I., Lundqvist E., Ingelman-Sundberg M., Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine, Lancet, 341, (1993)
[5]  
Dahl M.-L., Johansson I., Porsmyr Palmertz M., Ingelman-Sundberg M., Sjoqvist F., Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population, Clin Pharmacol Ther, 51, pp. 12-17, (1992)
[6]  
Eichelbaum M., Spannbrucker N., Steincke B., Dengler H.J., Defective N-oxidation of sparteine in man: A new pharmacogenetic defect, Eur J Clin Pharmacol, 16, pp. 183-187, (1979)
[7]  
Gaedigk A., Blum M., Gaedigk R., Eichelbaum M., Meyer U.A., Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism, Am J Hum Genet, 48, pp. 943-950, (1991)
[8]  
Goldstein J.A., Faletto M.B., Romkes-Sparks M., Sullivan T., Kitareewan S., Raucy J.L., Lasker J.M., Ghanayem B.I., Evidence that CYP2C19 is the major (S)-mephenytoin 4’-hydroxylase in humans, Biochemistry, 33, pp. 1743-1752, (1994)
[9]  
Heim M., Meyer U.A., Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification, Lancet, 336, pp. 529-532, (1990)
[10]  
Heim M.H., Meyer U.A., Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6, Genomics, 14, pp. 49-58, (1992)